Zenas BioPharma (NASDAQ:ZBIO) Shares Down 7.5% – What’s Next?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shares were down 7.5% on Monday . The company traded as low as $20.88 and last traded at $20.6240. Approximately 293,656 shares changed hands during trading, a decline of 68% from the average daily volume of 924,910 shares. The stock had previously closed at $22.30.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ZBIO. Morgan Stanley increased their price objective on shares of Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 17th. Wall Street Zen cut shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research note on Saturday. Zacks Research lowered shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 17th. Citigroup cut their price target on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $44.14.

Zenas BioPharma Stock Performance

The company has a quick ratio of 5.61, a current ratio of 5.61 and a debt-to-equity ratio of 0.32. The stock has a fifty day simple moving average of $23.18 and a 200-day simple moving average of $27.33. The company has a market capitalization of $1.21 billion, a P/E ratio of -2.70 and a beta of -1.94.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Monday, March 16th. The company reported ($4.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insider Transactions at Zenas BioPharma

In other Zenas BioPharma news, Director Hongbo Lu purchased 25,985 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was purchased at an average cost of $22.50 per share, with a total value of $584,662.50. Following the acquisition, the director directly owned 347,968 shares of the company’s stock, valued at approximately $7,829,280. This trade represents a 8.07% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Leon O. Moulder, Jr. acquired 57,000 shares of Zenas BioPharma stock in a transaction on Monday, February 2nd. The stock was acquired at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the purchase, the chief executive officer owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. This represents a 15.57% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 202,845 shares of company stock valued at $3,747,185 in the last three months. 22.00% of the stock is owned by corporate insiders.

Institutional Trading of Zenas BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of ZBIO. GF Fund Management CO. LTD. bought a new position in Zenas BioPharma in the 4th quarter worth approximately $38,000. Quarry LP raised its position in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Zenas BioPharma during the third quarter valued at $30,000. CWM LLC boosted its holdings in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Zenas BioPharma in the fourth quarter worth about $95,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.